He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Consider a 68-year-old retiree on Original Medicare who had a stage III melanoma removed this fall. Surgery took out the visible disease, and his oncologist has scheduled a year of Keytruda to lower the odds that it returns. Then he heard the latest discovery. A November trial in the New England Journal of Medicine reported that a personalized vaccine added to Keytruda kept 82.2% of patients free of return at two years, compared with 70.0% on Keytruda alone. He wants the vaccine. Medicare’s clinical trial rules decide whether he can get it and what he would pay.
What the Vaccine Trial Showed
Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) ran the Phase 3 INTerpath-001 trial in patients whose stage IIB-IV melanoma had been completely removed. After a median follow-up of 24.6 months, adding the vaccine, intismeran autogene, cut the risk of return or death by 42%. At two years, the estimated share remaining free of recurrence or death was 82.2% with the vaccine and Keytruda, versus 70.0% with Keytruda alone. That’s a 12.2-percentage-point difference.
The timing matters for an anxious patient. For the first six months, the two groups did about equally well (hazard ratio 0.99). The gap opened after that, with a 58% lower risk of return or death in a pre-specified analysis. Serious side effects (grade 3 or higher) occurred in 23.6% of the combination group and 20.3% of the control group. The overall survival data are still too early to judge.
Why No Doctor Can Prescribe It Yet
Each vaccine is made for one patient. A lab sequences DNA from the tumor and from normal tissue, picks up to 34 mutations found only in that patient’s cancer, and writes them into a single string of synthetic mRNA. Merck still calls the vaccine investigational and says the companies are “engaging with regulatory authorities.” Until the FDA approves it, the vaccine is not available as a routine Medicare-covered prescription. For now, eligible patients may be able to receive it through a clinical trial.
What Medicare Covers in a Clinical Trial
Medicare’s national coverage policy, NCD 310.1, distinguishes routine care from investigational treatment. In qualifying trials, Medicare covers eligible office visits, scans, lab work and care for complications, including certain services needed specifically because a patient is participating. Medicare covers the cost of administering an investigational treatment in a qualifying clinical trial, but generally not the experimental treatment itself. It also excludes services and supplies that trial sponsors ordinarily provide to participants free of charge.
Trial sponsors often provide experimental treatments at no charge, but patients should confirm that arrangement before enrolling. Medicare generally doesn’t pay for the investigational vaccine itself, and no verified commercial price exists for intismeran. The trial’s financial coordinator can explain what the sponsor supplies and which other costs remain.
His Share of the Routine Bills in 2026
On Original Medicare, routine trial care is charged like any other Part B service. He pays the $283 Part B deductible, then 20% of what Medicare okays. His approved Keytruda infusions work the same way, inside a trial or outside one. There is no annual out-of-pocket cap on Original Medicare, so that 20% keeps running for a full year of cancer care unless he has a Medigap policy such as Plan G, which pays the Part B coinsurance. If a side effect puts him in the hospital, the Part A deductible is $1,736 per benefit period.
For Medicare Advantage enrollees, Original Medicare generally pays for covered services in qualifying clinical trials. Their Advantage plan must cover the difference between Original Medicare’s cost-sharing and the plan’s in-network cost-sharing, and the enrollee isn’t charged Original Medicare’s Part A or Part B deductibles for trial coverage. Ask the plan what you’ll owe before enrolling, and watch for other hidden costs of serious illness in retirement (IRMAA surcharges and coverage gaps are the usual suspects, all mapped in our free Medicare guide).
Three Questions to Ask Your Oncology Team This Month
- Is any personalized vaccine trial recruiting patients like me? INTerpath-001 has already reported results, so you need a study that is open now. Check if your stage and the time since surgery meet the entry rules. ClinicalTrials.gov and the National Cancer Institute’s trial finder, both linked from Medicare’s coverage page, list current studies.
- Who pays for each item, in writing? Ask the trial’s financial coordinator to list three columns: what the sponsor provides free, what Medicare will bill as routine care, and anything that falls to you. Then compare your 20% exposure after the deductible with what your Medigap or Advantage plan pays.
- Will joining a trial change my okays treatment schedule? Keytruda alone produced a 70.0% two-year recurrence-free survival rate in this trial, and Medicare covers it for eligible patients today. Ask your oncologist whether a trial could affect your current treatment and whether you meet its enrollment requirements.
Contact [email protected] for any questions or corrections.
Gerelyn Terzo is the author of dividend investing handbook "Dividend Investing Strategies: How to Have Your Cake & Eat It Too." A veteran financial journalist, she covers agri-finance for outlets like Global AgInvesting and the broader stock market and personal finance for 24/7 Wall Street. She began at CNBC and later helped launch Fox Business in New York. Gerelyn currently resides in Woodland Park, Colorado and dabbles in nature photography as a hobby.
